MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Ann Oncol' source. Wed, 08 Feb 2012 08:41:14 +0100 http://www.medworm.com/index.php?rid=5625573&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22267211%26dopt%3DAbstract CONCLUSIONS: With increasing data availability demonstrating tumor-bone microenvironment interactions and routine incorporation of bone-related end points into CRPC trials, bone microenvironment-targeted agents are likely to become an increasingly important component of CRPC treatment. PMID: 22267211 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5625573 Fri, 20 Jan 2012 05:00:00 +0100 5625573 http://www.medworm.com/index.php?rid=5625574&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22267185%26dopt%3DAbstract Authors: Parise L, Kahle J, Schlaak M, Mauch C, Kurschat P PMID: 22267185 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5625574 Thu, 19 Jan 2012 05:00:00 +0100 5625574 http://www.medworm.com/index.php?rid=5625575&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22258366%26dopt%3DAbstract CONCLUSIONS: Good communication between patients and physicians is essential. Within this context, a web site such as Australian Cancer Trials may be an important tool to encourage discussion about clinical trial participation. PMID: 22258366 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5625575 Wed, 18 Jan 2012 05:00:00 +0100 5625575 http://www.medworm.com/index.php?rid=5625576&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22250183%26dopt%3DAbstract CONCLUSION: The G-8 shows good screening properties for identifying elderly cancer patients who could benefit from CGA. PMID: 22250183 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5625576 Mon, 16 Jan 2012 05:00:00 +0100 5625576 http://www.medworm.com/index.php?rid=5579607&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F12%252F30%252018.06%2522%255BMHDA%255D%253A%25222012%252F01%252F12%252011.36%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F12%252F30%252018.06%2522%255BEDAT%255D%29%29 31 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2012/01/12PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5579607 Thu, 12 Jan 2012 16:36:01 +0100 5579607 http://www.medworm.com/index.php?rid=5551749&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F12%252F24%252017.18%2522%255BMHDA%255D%253A%25222011%252F12%252F30%252018.06%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F12%252F24%252017.18%2522%255BEDAT%255D%29%29 16 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/12/30PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5551749 Fri, 30 Dec 2011 23:06:01 +0100 5551749 http://www.medworm.com/index.php?rid=5537108&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F12%252F12%252023.36%2522%255BMHDA%255D%253A%25222011%252F12%252F24%252017.18%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F12%252F12%252023.36%2522%255BEDAT%255D%29%29 184 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/12/24PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5537108 Sat, 24 Dec 2011 22:18:01 +0100 5537108 http://www.medworm.com/index.php?rid=5494912&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22147734%26dopt%3DAbstract CONCLUSIONS: Our study supports the hypothesis that elevated BMI may be a risk factor for small intestine cancer. An etiologic role of alcohol drinking was suggested. Our results reinforce the existing evidence that the epidemiology of small intestine cancer resembles that of colorectal cancer. PMID: 22147734 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5494912 Tue, 06 Dec 2011 05:00:00 +0100 5494912 http://www.medworm.com/index.php?rid=5459497&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22123733%26dopt%3DAbstract CONCLUSIONS: These findings suggest that diets rich in animal products, cereals, and fats are positively related to laryngeal cancer, and those rich in fruit and vegetables inversely related to oral and pharyngeal cancer. PMID: 22123733 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5459497 Mon, 28 Nov 2011 05:00:00 +0100 5459497 http://www.medworm.com/index.php?rid=5443577&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F11%252F19%252017.00%2522%255BMHDA%255D%253A%25222011%252F11%252F25%252012.54%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F11%252F19%252017.00%2522%255BEDAT%255D%29%29 19 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/11/25PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5443577 Fri, 25 Nov 2011 17:54:01 +0100 5443577 http://www.medworm.com/index.php?rid=5426006&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F11%252F07%252013.50%2522%255BMHDA%255D%253A%25222011%252F11%252F19%252017.00%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F11%252F07%252013.50%2522%255BEDAT%255D%29%29 27 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/11/19PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5426006 Sat, 19 Nov 2011 22:00:02 +0100 5426006 http://www.medworm.com/index.php?rid=5382512&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F10%252F20%252009.10%2522%255BMHDA%255D%253A%25222011%252F11%252F07%252013.50%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F10%252F20%252009.10%2522%255BEDAT%255D%29%29 65 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/11/07PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5382512 Mon, 07 Nov 2011 18:50:01 +0100 5382512 http://www.medworm.com/index.php?rid=5331772&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F10%252F15%252003.14%2522%255BMHDA%255D%253A%25222011%252F10%252F20%252009.10%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F10%252F15%252003.14%2522%255BEDAT%255D%29%29 70 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/10/20PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5331772 Thu, 20 Oct 2011 13:10:01 +0100 5331772 http://www.medworm.com/index.php?rid=5315141&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21994214%26dopt%3DAbstract CONCLUSION: A statistical analysis of these 28 cases suggests a nonrandom association between GIST and DT. Further studies may be able to elucidate the underlying biology responsible for this association. PMID: 21994214 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5315141 Wed, 12 Oct 2011 04:00:00 +0100 5315141 http://www.medworm.com/index.php?rid=5315146&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21989327%26dopt%3DAbstract CONCLUSIONS: Eribulin exhibited efficacy and tolerability in Japanese patients with heavily pretreated MBC. PMID: 21989327 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5315146 Tue, 11 Oct 2011 04:00:00 +0100 5315146 http://www.medworm.com/index.php?rid=5315145&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21989328%26dopt%3DAbstract CONCLUSIONS: In younger patients with aaIPI 0 or 1, CNS relapse/progression is very rare; in patients with aaIPI 2 or 3, the risk is higher (up to 10%) and requires new diagnostic strategies and treatment. PMID: 21989328 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5315145 Tue, 11 Oct 2011 04:00:00 +0100 5315145 http://www.medworm.com/index.php?rid=5315144&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21989329%26dopt%3DAbstract Authors: Meadows AT PMID: 21989329 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5315144 Tue, 11 Oct 2011 04:00:00 +0100 5315144 http://www.medworm.com/index.php?rid=5315143&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21989330%26dopt%3DAbstract CONCLUSION: Our findings suggest that CCND1A870G may be useful in predicting clinical outcome in HER2-positive mBC patients treated with lapatinib plus capecitabine. PMID: 21989330 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5315143 Tue, 11 Oct 2011 04:00:00 +0100 5315143 http://www.medworm.com/index.php?rid=5315142&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21989331%26dopt%3DAbstract Authors: Paydas S PMID: 21989331 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5315142 Tue, 11 Oct 2011 04:00:00 +0100 5315142 http://www.medworm.com/index.php?rid=5315149&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21986093%26dopt%3DAbstract CONCLUSIONS: ESR1 aberrations were associated with HER2 status, Ki-67 labeling index and ER and PgR levels. When combined with HER2, ESR1 may be prognostic but should not be used for endocrine treatment selection in postmenopausal women with endocrine-responsive early breast cancer. PMID: 21986093 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5315149 Mon, 10 Oct 2011 04:00:00 +0100 5315149 http://www.medworm.com/index.php?rid=5315148&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21986094%26dopt%3DAbstract CONCLUSIONS: In this combined analysis of three prospective trials, ONJ was infrequent, management was mostly conservative, and healing occurred in over one-third of the patients. Educating physicians about oral health before and during bone-targeted therapy may help reduce ONJ incidence and improve outcomes. PMID: 21986094 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5315148 Mon, 10 Oct 2011 04:00:00 +0100 5315148 http://www.medworm.com/index.php?rid=5315147&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21986095%26dopt%3DAbstract CONCLUSION: Only 24%-69% were eligible for targeted therapy trials but 66% received anticancer treatment. Clinical trials in patients with advanced NSCLC need to be more representative of the majority of patients. PMID: 21986095 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5315147 Mon, 10 Oct 2011 04:00:00 +0100 5315147 http://www.medworm.com/index.php?rid=5301071&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21980193%26dopt%3DAbstract CONCLUSIONS: Reduction from IFRT to INRT decreased the volumes of lungs, breasts and thyroid receiving high-dose radiation, suggesting the potential to reduce long-term second malignancy risks. VMAT may be useful for patients with pre-existing heart disease by minimising further cardiac toxicity risks. PMID: 21980193 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5301071 Thu, 06 Oct 2011 04:00:00 +0100 5301071 http://www.medworm.com/index.php?rid=5301075&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21965473%26dopt%3DAbstract CONCLUSIONS: In this large retrospective study, CTCs were strongly predictive of survival in all MBC subtypes except HER2+ patients who had been treated with targeted therapy. Our results clearly demonstrate the value of enumerating CTCs in MBC and strongly suggest an interesting biological implication in the HER2+ subset of patients that need to be further explored. PMID: 21965473 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5301075 Wed, 05 Oct 2011 04:00:00 +0100 5301075 http://www.medworm.com/index.php?rid=5301074&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21976386%26dopt%3DAbstract CONCLUSION: Carboplatin-PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients. PMID: 21976386 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5301074 Wed, 05 Oct 2011 04:00:00 +0100 5301074 http://www.medworm.com/index.php?rid=5301073&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21976387%26dopt%3DAbstract CONCLUSIONS: Bevacizumab did increase the risk of LVD and hemorrhagic events. The addition of bevacizumab to chemotherapy in patients with metastatic breast cancer was not associated with a significant increase in grade ≥3 arterial or venous thromboembolic events, GI perforation, or fatal events. PMID: 21976387 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5301073 Tue, 04 Oct 2011 04:00:00 +0100 5301073 http://www.medworm.com/index.php?rid=5301072&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21976388%26dopt%3DAbstract Authors: Thanopoulou E, Trehan P, Judson IR PMID: 21976388 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5301072 Tue, 04 Oct 2011 04:00:00 +0100 5301072 http://www.medworm.com/index.php?rid=5282868&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21965471%26dopt%3DAbstract CONCLUSIONS: The recurrence risk for the patients with aneuploid tumor is higher than the patients with diploid tumor in EAC of the endometrium. Based on DNA index with cut-off 1.20, aneuploid tumors can be separated into two subgroups with different recurrence pattern and survival. PMID: 21965471 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5282868 Fri, 30 Sep 2011 04:00:00 +0100 5282868 http://www.medworm.com/index.php?rid=5282867&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21965472%26dopt%3DAbstract CONCLUSIONS: FCM gives far more positive results than CC. However, a positive FCM result did not translate into a significant increase in CNS relapse rate in this histologically uniform population receiving CNS prophylaxis. PMID: 21965472 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5282867 Fri, 30 Sep 2011 04:00:00 +0100 5282867 http://www.medworm.com/index.php?rid=5266013&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F09%252F24%252009.39%2522%255BMHDA%255D%253A%25222011%252F09%252F29%252020.34%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F09%252F24%252009.39%2522%255BEDAT%255D%29%29 76 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/09/29PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5266013 Fri, 30 Sep 2011 00:34:55 +0100 5266013 http://www.medworm.com/index.php?rid=5249532&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21940784%26dopt%3DAbstract Authors: Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold C, Pujol JL, Stahel R, Thatcher N, Vansteenkiste J, Minichsdorfer C, Zöchbauer-Müller S, Pirker R, Zielinski CC, Abstract The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG), which has published such consensus statements in the years 2002 and 2005 (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer-update 2004. Lung Cancer 2005; 50: 129-137). The principle of all CECOG consensus is such that evidence-based recommendation... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5249532 Thu, 22 Sep 2011 04:00:00 +0100 5249532 http://www.medworm.com/index.php?rid=5249531&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21940785%26dopt%3DAbstract CONCLUSIONS: Celecoxib can be used effectively and safely to prevent capecitabine-related HFS. PMID: 21940785 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5249531 Thu, 22 Sep 2011 04:00:00 +0100 5249531 http://www.medworm.com/index.php?rid=5249533&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21937705%26dopt%3DAbstract CONCLUSIONS: This trial failed to demonstrate superiority of vinorelbine/gemcitabine doublet over single-agent capecitabine in terms of PFS. Given the favorable toxicity and convenience of oral administration, single-agent capecitabine is recommended for compliant patients. PMID: 21937705 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5249533 Wed, 21 Sep 2011 04:00:00 +0100 5249533 http://www.medworm.com/index.php?rid=5249535&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21930686%26dopt%3DAbstract CONCLUSION: IMM-101 is safe and well tolerated and there is a rationale for studying IMM-101 at a nominal 1.0-mg dose to complement conventional cytotoxic therapy for patients with advanced cancer. PMID: 21930686 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5249535 Mon, 19 Sep 2011 04:00:00 +0100 5249535 http://www.medworm.com/index.php?rid=5249534&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21930687%26dopt%3DAbstract CONCLUSIONS: Two different trabectedin schedules showed modest activity in metastatic CRPC. Further studies may require identification of predictive factors of response in prostate cancer. PMID: 21930687 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5249534 Mon, 19 Sep 2011 04:00:00 +0100 5249534 http://www.medworm.com/index.php?rid=5249537&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21926398%26dopt%3DAbstract CONCLUSION: An EZH2 SNP may be useful to predict clinical outcome in mCRC patients. PMID: 21926398 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5249537 Fri, 16 Sep 2011 04:00:00 +0100 5249537 http://www.medworm.com/index.php?rid=5249536&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21926399%26dopt%3DAbstract CONCLUSION: Two escBEACOPP plus six sBEACOPP is efficacious in advanced-stage high-risk HL. We document a high incidence of aseptic bone necrosis, possibly related to prednisolone. PMID: 21926399 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5249536 Fri, 16 Sep 2011 04:00:00 +0100 5249536 http://www.medworm.com/index.php?rid=5234595&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21917737%26dopt%3DAbstract CONCLUSIONS: In our experience, the majority of the patients accepted skin biopsies as well as tumour biopsies. Sequential tumour and skin biopsies are feasible and safe during early-phase clinical trials, even when patients are exposed to anti-angiogenic agents. The real scientific value of such biopsies for dose selection in phase I trials has yet to be established. PMID: 21917737 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5234595 Wed, 14 Sep 2011 04:00:00 +0100 5234595 http://www.medworm.com/index.php?rid=5234594&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21917738%26dopt%3DAbstract CONCLUSIONS: Using a western blot assay, nearly all noncardia GC were classified as H. pylori positive and the OR was more than threefold higher than the OR assessed by ELISA, supporting the hypothesis that H. pylori infection is a necessary condition for noncardia GC. PMID: 21917738 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5234594 Wed, 14 Sep 2011 04:00:00 +0100 5234594 http://www.medworm.com/index.php?rid=5234593&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21917739%26dopt%3DAbstract Authors: Braga S PMID: 21917739 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5234593 Tue, 13 Sep 2011 04:00:00 +0100 5234593 http://www.medworm.com/index.php?rid=5220751&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21908496%26dopt%3DAbstract CONCLUSIONS: Nuclear PARP-1 is overexpressed during the malignant transformation of the breast, particularly in triple-negative tumors, and independently predicts poor prognosis in operable invasive breast cancer. PMID: 21908496 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220751 Fri, 09 Sep 2011 04:00:00 +0100 5220751 http://www.medworm.com/index.php?rid=5220753&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21903604%26dopt%3DAbstract CONCLUSION: Before starting aromatase inhibitor therapy for breast cancer, a large proportion of women had a vitamin D insufficiency and vertebral fractures. PMID: 21903604 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220753 Wed, 07 Sep 2011 04:00:00 +0100 5220753 http://www.medworm.com/index.php?rid=5220752&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21903605%26dopt%3DAbstract CONCLUSION: Eribulin mesylate demonstrated activity and a relatively favorable toxicity profile in metastatic CRPC. PMID: 21903605 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220752 Wed, 07 Sep 2011 04:00:00 +0100 5220752 http://www.medworm.com/index.php?rid=5220759&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21896539%26dopt%3DAbstract CONCLUSION: Oral capecitabine is an effective alternative to bolus 5-FU/FA as adjuvant treatment of patients with stage III colon cancer with efficacy benefits maintained at 5 years and in older patients. PMID: 21896539 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220759 Tue, 06 Sep 2011 04:00:00 +0100 5220759 http://www.medworm.com/index.php?rid=5220758&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21896540%26dopt%3DAbstract CONCLUSIONS: Treatment of advanced PDAC with GEM + ET was generally well tolerated. GEM + ET showed beneficial survival and efficacy. A randomized phase III trial should confirm this positive trend. PMID: 21896540 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220758 Tue, 06 Sep 2011 04:00:00 +0100 5220758 http://www.medworm.com/index.php?rid=5220757&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21896541%26dopt%3DAbstract CONCLUSION: Toxicity and chemotherapy resistance are still major limitations in the treatment of patients with MBC. Further research into new cytotoxic compounds is needed in order to maximise benefit, whilst minimising toxicity. PMID: 21896541 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220757 Tue, 06 Sep 2011 04:00:00 +0100 5220757 http://www.medworm.com/index.php?rid=5220756&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21896542%26dopt%3DAbstract CONCLUSIONS: There is some evidence of enhanced incremental accuracy for some of the above-mentioned tests where used as add-on in subjects selected to more than one imaging modality, with little evidence to support their application as a replacement to BS in first-line imaging of BM. PET/CT appears to have high accuracy and is recommended for further evaluation. PMID: 21896542 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220756 Tue, 06 Sep 2011 04:00:00 +0100 5220756 http://www.medworm.com/index.php?rid=5220755&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21896543%26dopt%3DAbstract CONCLUSION: ASLND, involving expensive techniques, was finally less expensive than ALND. The length of hospital stay was the cost driver of these procedures. The current observational study points the heterogeneous practices for this validated and largely diffused technique. Several technical choices have an impact on the cost of ASLND, as intraoperative analysis allowing to reduce rehospitalization rate for secondary lymphadenectomy or preoperative scintigraphy, suggesting possible savings on hospital resources. PMID: 21896543 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220755 Tue, 06 Sep 2011 04:00:00 +0100 5220755 http://www.medworm.com/index.php?rid=5220754&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21898417%26dopt%3DAbstract Authors: Namm JP, Li Q, Lao X, Lubman DM, He J, Liu Y, Zhu J, Wei S, Chang AE Abstract Over the years, the role of B cells in the host immune response to malignancy has been overshadowed by our focus on T cells. Nevertheless, B cells play important roles as antigen-presenting cells and in the production of antibodies. Furthermore, B cells can function as effector cells that mediate tumor destruction on their own. This review will highlight the various functions of B cells that are involved in the host response to tumor. J. Surg. Oncol. © 2011 Wiley-Liss, Inc. PMID: 21898417 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220754 Tue, 06 Sep 2011 04:00:00 +0100 5220754 http://www.medworm.com/index.php?rid=5220761&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21890909%26dopt%3DAbstract CONCLUSIONS: The proportion of patients with multiple metastatic sites is higher in young patients. The rates of bone (10%-49%) and brain (2%-16%) metastases are nonnegligible in mRCC patients. PMID: 21890909 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220761 Fri, 02 Sep 2011 04:00:00 +0100 5220761 http://www.medworm.com/index.php?rid=5220760&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21890910%26dopt%3DAbstract CONCLUSIONS: Both general and abdominal fatness increases pancreatic cancer risk. Among nonsmokers, risk increases even among persons within the normal BMI range. PMID: 21890910 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5220760 Fri, 02 Sep 2011 04:00:00 +0100 5220760 http://www.medworm.com/index.php?rid=5179878&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21878429%26dopt%3DAbstract Authors: Thiery-Vuillemin A, Montange D, Kalbacher E, Maurina T, Nguyen T, Royer B, Bouchet S, Bazan F, Curtit E, Pivot X PMID: 21878429 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5179878 Wed, 31 Aug 2011 23:00:00 +0100 5179878 http://www.medworm.com/index.php?rid=5179880&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21878427%26dopt%3DAbstract CONCLUSIONS: In this longitudinal cohort study, we observed a gradual decline in diastolic parameters after cisplatin-based chemotherapy for testicular cancer, whereas the rate of systolic dysfunction remains low. The association of larger declines in diastolic parameters with hypertension and obesity stresses the need to monitor and treat cardiovascular risk factors. PMID: 21878427 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5179880 Sun, 28 Aug 2011 23:00:00 +0100 5179880 http://www.medworm.com/index.php?rid=5179879&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21878428%26dopt%3DAbstract Authors: Langendijk JA, Oosting SF PMID: 21878428 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5179879 Sun, 28 Aug 2011 23:00:00 +0100 5179879 http://www.medworm.com/index.php?rid=5179881&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21873272%26dopt%3DAbstract CONCLUSION: Vx-001 vaccine was well tolerated and induced a TERT-specific immunological response, which was significantly correlated with improved clinical outcome. PMID: 21873272 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5179881 Wed, 24 Aug 2011 23:00:00 +0100 5179881 http://www.medworm.com/index.php?rid=5179882&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21868392%26dopt%3DAbstract Authors: Krauskopf E PMID: 21868392 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5179882 Tue, 23 Aug 2011 23:00:00 +0100 5179882 http://www.medworm.com/index.php?rid=5160056&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21865152%26dopt%3DAbstract CONCLUSION: The combination of cetuximab and weekly paclitaxel was active and well tolerated by these poor prognosis patients and may be an option for the treatment of medically unfit patients, particularly those for whom platinum is contraindicated. PMID: 21865152 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5160056 Mon, 22 Aug 2011 23:00:00 +0100 5160056 http://www.medworm.com/index.php?rid=5160060&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21859897%26dopt%3DAbstract Authors: Galofré JC, Gómez-Sáez JM, Escola CA, Anda E, Calleja A, Donnay S, Lucas-Martin A, Menéndez-Torre E, Pereg V, Pérez-Corral B, Santamaría J, Riesco-Eizaguirre G, Zafon C, PMID: 21859897 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5160060 Sun, 21 Aug 2011 23:00:00 +0100 5160060 http://www.medworm.com/index.php?rid=5160059&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21859898%26dopt%3DAbstract CONCLUSIONS: YM155 has modest activity in taxane-pretreated CRPC with 25% of patients having prolonged stable disease (≥18 weeks). The regimen appears to be well tolerated. Based on the mechanism of action and preclinical evidence of synergy with docetaxel (Taxotere), YM155 combined with docetaxel is being evaluated in patients with CRPC. PMID: 21859898 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5160059 Sun, 21 Aug 2011 23:00:00 +0100 5160059 http://www.medworm.com/index.php?rid=5160058&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21859899%26dopt%3DAbstract Authors: Escobar C, Munker R, Thomas JO, Li BD, Burton GV Abstract Desmoid tumors (DTs) are histologically benign proliferations of stromal cells but may grow locally aggressive. Overall, DTs are rare (0.03% of all neoplasms). A minority of DTs is associated with Gardner syndrome and mutations of the familial adenomatous polyposis (FAP) gene. Most spontaneous DTs are associated with mutations of the beta-catenin gene. This mutation results in the activation of Wnt/catenin signaling. Due to their variable clinical presentation and behavior, no standard approach for DTs can be recommended. In most cases of DTs of the extremities surgical extirpation is indicated, whereas in many other cases, a multimodal and multidisciplinary concept should be followed. In this review article, we dis... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5160058 Sun, 21 Aug 2011 23:00:00 +0100 5160058 http://www.medworm.com/index.php?rid=5160057&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21859900%26dopt%3DAbstract CONCLUSION: The study was underpowered to demonstrate that AC with cisplatin and gemcitabine improves OS and disease-free survival in patients with MIBC. PMID: 21859900 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5160057 Sun, 21 Aug 2011 23:00:00 +0100 5160057 http://www.medworm.com/index.php?rid=5142370&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F08%252F09%252018.15%2522%255BMHDA%255D%253A%25222011%252F08%252F20%252003.28%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F08%252F09%252018.15%2522%255BEDAT%255D%29%29 44 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/08/20PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5142370 Sat, 20 Aug 2011 07:28:02 +0100 5142370 http://www.medworm.com/index.php?rid=5108177&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F07%252F26%252011.30%2522%255BMHDA%255D%253A%25222011%252F08%252F09%252018.15%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F07%252F26%252011.30%2522%255BEDAT%255D%29%29 18 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/08/09PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5108177 Tue, 09 Aug 2011 22:15:02 +0100 5108177 http://www.medworm.com/index.php?rid=5011799&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21734221%26dopt%3DAbstract Authors: Sehouli J, Alfaro V, González-Martín A The effectiveness of platinum re-treatment in relapsed ovarian cancer depends on relapse-free/treatment-free intervals. Platinum agents can be effectively readministered to platinum-sensitive patients (relapsing >12 months after platinum), but efficacy is lower in partially platinum-sensitive (PPS) disease (relapsing 6-12 months after platinum). There is no clear standard treatment challenging PPS patients. Survival data in this subset with chemotherapy combinations such as pegylated liposomal doxorubicin (PLD) plus carboplatin or gemcitabine plus PLD are available from phase II trials ranging from 16 to 21 months. Recent results from OVA-301 phase III randomized trial evaluating trabectedin plus PLD showed the longest median overall... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5011799 Tue, 05 Jul 2011 23:00:00 +0100 5011799 http://www.medworm.com/index.php?rid=5011800&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21727198%26dopt%3DAbstract Authors: Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus PE, Sorensen JB, Felip E, The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21st and 22nd May 2010 with the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics and medical, surgical and radiation oncology. Before the conference, the expert panel prepared clinically relevant questions concerning five areas as follows: early and locally advanced non-small-cell lung cancer (NSCLC), first-line metastatic NSCLC, second-/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer (SCLC) to be addressed through discussion at the Consensus Conference. All relevant scientific literature for each question was reviewed in ... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5011800 Sun, 03 Jul 2011 23:00:00 +0100 5011800 http://www.medworm.com/index.php?rid=5011801&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21719645%26dopt%3DAbstract Authors: Casali PG PMID: 21719645 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5011801 Wed, 29 Jun 2011 23:00:00 +0100 5011801 http://www.medworm.com/index.php?rid=5011802&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21715566%26dopt%3DAbstract In conclusion, although we have learned a lot from the use of CMF, many questions are still open and hopefully stimulate our thinking, as clinicians, leading us to find new and more effective ways to treat breast cancer. PMID: 21715566 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5011802 Tue, 28 Jun 2011 23:00:00 +0100 5011802 http://www.medworm.com/index.php?rid=5011806&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21709137%26dopt%3DAbstract Authors: Chu D, Zhang Z, Li Y, Ji G PMID: 21709137 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5011806 Sun, 26 Jun 2011 23:00:00 +0100 5011806 http://www.medworm.com/index.php?rid=5011805&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21709138%26dopt%3DAbstract Authors: Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, Cohen D, Wasan H This paper explores the enigma of cancer of unknown primary (CUP) in relation to rapidly improving molecular diagnostic approaches. It is based on the first global collaboration meeting on improving research and clinical outcomes in CUP organized by the CUP Foundation. We review the difficulties of classifying this widely heterogeneous disease and the available diagnostic and pathological evaluative techniques, focusing on molecular profiling. Retrospective studies in CUP patients are shown to provide indirect validation of the accuracy of several platforms of gene expression profiling assays that may identify CUP subsets that respond favorably to active chemotherapy regimens. This review ... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5011805 Sun, 26 Jun 2011 23:00:00 +0100 5011805 http://www.medworm.com/index.php?rid=5011804&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21709139%26dopt%3DAbstract Authors: Masuda S PMID: 21709139 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5011804 Sun, 26 Jun 2011 23:00:00 +0100 5011804 http://www.medworm.com/index.php?rid=5011803&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21709140%26dopt%3DAbstract Authors: Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather than gene expression array criteria. In general, systemic therapy recommendations follow the subtype classification. Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtype. Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=5011803 Sun, 26 Jun 2011 23:00:00 +0100 5011803 http://www.medworm.com/index.php?rid=4968090&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F06%252F12%252006.15%2522%255BMHDA%255D%253A%25222011%252F06%252F26%252014.45%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F06%252F12%252006.15%2522%255BEDAT%255D%29%29 47 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/06/26PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4968090 Sun, 26 Jun 2011 18:45:02 +0100 4968090 http://www.medworm.com/index.php?rid=4922174&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F05%252F29%252002.15%2522%255BMHDA%255D%253A%25222011%252F06%252F12%252006.15%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F05%252F29%252002.15%2522%255BEDAT%255D%29%29 18 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/06/12PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4922174 Sun, 12 Jun 2011 10:15:02 +0100 4922174 http://www.medworm.com/index.php?rid=4876192&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21617019%26dopt%3DAbstract CONCLUSIONS: In the chosen patient population, vatalanib QD and TDD dosing demonstrated potential benefits in tumor size reduction, DCR, and survival. PMID: 21617019 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876192 Wed, 25 May 2011 23:00:00 +0100 4876192 http://www.medworm.com/index.php?rid=4876191&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21617020%26dopt%3DAbstract CONCLUSION: This meta-analysis shows that milk and total dairy products, but not cheese or other dairy products, are associated with a reduction in colorectal cancer risk. PMID: 21617020 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876191 Wed, 25 May 2011 23:00:00 +0100 4876191 http://www.medworm.com/index.php?rid=4876194&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21610154%26dopt%3DAbstract CONCLUSIONS: Patients with advanced NSCLC and SD following first-line platinum-based doublet chemotherapy derive a significant OS benefit from maintenance erlotinib therapy. PMID: 21610154 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876194 Mon, 23 May 2011 23:00:00 +0100 4876194 http://www.medworm.com/index.php?rid=4876193&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21610155%26dopt%3DAbstract CONCLUSIONS: Lipofilling seems to be a safe procedure in breast cancer patients. Longer follow-up and further experiences from oncological series are urgently required to confirm these findings. PMID: 21610155 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876193 Mon, 23 May 2011 23:00:00 +0100 4876193 http://www.medworm.com/index.php?rid=4876195&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21606209%26dopt%3DAbstract CONCLUSIONS: The proposed revisions to the grading system and updated management guidelines described here represent important developments toward the more appropriate grading and effective management of radiation dermatitis in patients receiving cetuximab plus radiotherapy for LA SCCHN. PMID: 21606209 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876195 Sun, 22 May 2011 23:00:00 +0100 4876195 http://www.medworm.com/index.php?rid=4876196&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21602260%26dopt%3DAbstract CONCLUSION: CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL. PMID: 21602260 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876196 Thu, 19 May 2011 23:00:00 +0100 4876196 http://www.medworm.com/index.php?rid=4876198&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21597096%26dopt%3DAbstract CONCLUSIONS: German cancer survival estimates are mostly higher than the 2000-2002 pan-European estimates. Further research is needed to investigate causes responsible for differences between German and USA cancer survival rates. PMID: 21597096 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876198 Wed, 18 May 2011 23:00:00 +0100 4876198 http://www.medworm.com/index.php?rid=4876197&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21597097%26dopt%3DAbstract CONCLUSIONS: We found significant association between BMI and colorectal cancer risk by pooling of data from cohort studies with considerable number of subjects among Japanese population. This information is important in cancer control planning, especially in Asian population. PMID: 21597097 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876197 Wed, 18 May 2011 23:00:00 +0100 4876197 http://www.medworm.com/index.php?rid=4876201&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21586686%26dopt%3DAbstract CONCLUSIONS: Diagnosis of BCa is associated with increased risks of dying of various causes, including external causes, heart failure, diseases of pulmonary circulation, and gastrointestinal disease. The study fulfills the gap in knowledge of death causes in BCa patients and suggests to draw more attention to comorbidities. PMID: 21586686 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876201 Mon, 16 May 2011 23:00:00 +0100 4876201 http://www.medworm.com/index.php?rid=4876200&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21586687%26dopt%3DAbstract CONCLUSIONS: We show that MSS SBAs are more similar to colorectal than to gastric cancer, based on the 27 genome-wide DNA copy number profiles that are currently available. These molecular similarities provide added support for treatment of MSS small bowel cancers according to colorectal cancer regimens. PMID: 21586687 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876200 Mon, 16 May 2011 23:00:00 +0100 4876200 http://www.medworm.com/index.php?rid=4876199&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21586688%26dopt%3DAbstract CONCLUSIONS: Our data confirm that EBV-specific CTL therapy is safe and associated with antitumor activity in patients with advanced NPC. The use of lymphodepleting chemotherapy before high-dose CTL infusion did not enhance the clinical benefit observed in our previous series. PMID: 21586688 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876199 Mon, 16 May 2011 23:00:00 +0100 4876199 http://www.medworm.com/index.php?rid=4876203&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21576284%26dopt%3DAbstract CONCLUSION: BMS-599626 was generally well tolerated, with disease stabilization across a range of tumor types and doses. PMID: 21576284 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876203 Sun, 15 May 2011 23:00:00 +0100 4876203 http://www.medworm.com/index.php?rid=4876202&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21576285%26dopt%3DAbstract CONCLUSIONS: A single dose of AS03-adjuvanted A/H1N1 vaccine triggered a low immune response in cancer patients on chemotherapy depending on their treatment type and frequency. Two doses are needed for these cancer patients. PMID: 21576285 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4876202 Sun, 15 May 2011 23:00:00 +0100 4876202 http://www.medworm.com/index.php?rid=4822033&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F04%252F30%252012.45%2522%255BMHDA%255D%253A%25222011%252F05%252F14%252013.30%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F04%252F30%252012.45%2522%255BEDAT%255D%29%29 71 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/05/14PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4822033 Sat, 14 May 2011 17:30:02 +0100 4822033 http://www.medworm.com/index.php?rid=4768405&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F03%252F31%252022.30%2522%255BMHDA%255D%253A%25222011%252F04%252F30%252012.45%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F03%252F31%252022.30%2522%255BEDAT%255D%29%29 39 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/04/30PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4768405 Sat, 30 Apr 2011 16:45:02 +0100 4768405 http://www.medworm.com/index.php?rid=4662176&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F03%252F17%252010.45%2522%255BMHDA%255D%253A%25222011%252F03%252F31%252022.30%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F03%252F17%252010.45%2522%255BEDAT%255D%29%29 82 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/03/31PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4662176 Fri, 01 Apr 2011 02:30:03 +0100 4662176 http://www.medworm.com/index.php?rid=4601119&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F03%252F03%252003.30%2522%255BMHDA%255D%253A%25222011%252F03%252F17%252010.45%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F03%252F03%252003.30%2522%255BEDAT%255D%29%29 54 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/03/17PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4601119 Thu, 17 Mar 2011 14:45:03 +0100 4601119 http://www.medworm.com/index.php?rid=4540779&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F02%252F17%252002.00%2522%255BMHDA%255D%253A%25222011%252F03%252F03%252003.30%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F02%252F17%252002.00%2522%255BEDAT%255D%29%29 65 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/03/03PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4540779 Thu, 03 Mar 2011 08:30:03 +0100 4540779 http://www.medworm.com/index.php?rid=4483634&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F01%252F31%252005.45%2522%255BMHDA%255D%253A%25222011%252F02%252F17%252002.00%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F01%252F31%252005.45%2522%255BEDAT%255D%29%29 56 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/02/17PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4483634 Thu, 17 Feb 2011 07:00:02 +0100 4483634 http://www.medworm.com/index.php?rid=4415090&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222011%252F01%252F16%252012.30%2522%255BMHDA%255D%253A%25222011%252F01%252F31%252005.45%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222011%252F01%252F16%252012.30%2522%255BEDAT%255D%29%29 80 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/01/31PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4415090 Mon, 31 Jan 2011 10:45:02 +0100 4415090 http://www.medworm.com/index.php?rid=4353414&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F12%252F24%252001.00%2522%255BMHDA%255D%253A%25222011%252F01%252F16%252012.30%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F12%252F24%252001.00%2522%255BEDAT%255D%29%29 21 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2011/01/16PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4353414 Sun, 16 Jan 2011 17:30:04 +0100 4353414 http://www.medworm.com/index.php?rid=4285320&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21169472%26dopt%3DAbstract Authors: PMID: 21169472 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4285320 Fri, 24 Dec 2010 06:00:19 +0100 4285320 http://www.medworm.com/index.php?rid=4285319&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21169473%26dopt%3DAbstract Authors: Garassino MC, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G, Scanni A, Broggini M PMID: 21169473 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4285319 Fri, 24 Dec 2010 06:00:15 +0100 4285319 http://www.medworm.com/index.php?rid=4285318&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21169474%26dopt%3DAbstract Authors: Capdevila J, Díez Miranda I, Obiols G, Tabernero J PMID: 21169474 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4285318 Fri, 24 Dec 2010 06:00:12 +0100 4285318 http://www.medworm.com/index.php?rid=4285317&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21169475%26dopt%3DAbstract Authors: Arkenau HK PMID: 21169475 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4285317 Fri, 24 Dec 2010 06:00:09 +0100 4285317 http://www.medworm.com/index.php?rid=4285316&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21169476%26dopt%3DAbstract Authors: Storey DJ, Sakala M, McLean CM, Phillips HA, Dawson LK, Wall LR, Fallon MT, Clive S PMID: 21169476 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4285316 Fri, 24 Dec 2010 06:00:06 +0100 4285316 http://www.medworm.com/index.php?rid=4256836&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F12%252F03%252004.15%2522%255BMHDA%255D%253A%25222010%252F12%252F14%252011.20%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F12%252F03%252004.15%2522%255BEDAT%255D%29%29 127 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/12/14PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4256836 Tue, 14 Dec 2010 16:20:09 +0100 4256836 http://www.medworm.com/index.php?rid=4204639&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21098619%26dopt%3DAbstract Authors: Bujko K, Glynne-Jones R, Bujko M PMID: 21098619 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4204639 Sat, 27 Nov 2010 08:40:10 +0100 4204639 http://www.medworm.com/index.php?rid=4204640&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21098618%26dopt%3DAbstract CONCLUSIONS: The results of the present study suggested that a presence of KRAS mutations in mucinous ovarian cancer and CFDNA and p53-Ab in serous tumors was correlated with the highest risk of cancer progression. PMID: 21098618 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4204640 Tue, 23 Nov 2010 00:00:00 +0100 4204640 http://www.medworm.com/index.php?rid=4204641&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21097988%26dopt%3DAbstract Authors: Verma S, Ewer MS The cardiotoxicity of anthracyclines, trastuzumab and other agents is of special importance to adjuvant breast cancer patients whose life expectancy is restored to normal but who may be left with cardiac abnormalities that can present years later. We systematically reviewed the design of current trials (including adjuvant studies) on the clinicaltrials.gov Web site. Surprisingly few specify primary or secondary cardiac end points. Although cardiac ultrasound (echocardiography) and multiple uptake gated acquisition scintigraphy remain the most frequent techniques for estimating left ventricular ejection fraction, there is no consistency in the degree of reduction from baseline or absolute value taken as indicating cardiotoxicity. The details given do not sugges... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4204641 Mon, 22 Nov 2010 00:00:00 +0100 4204641 http://www.medworm.com/index.php?rid=4204642&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21097554%26dopt%3DAbstract CONCLUSION: T and high-dose RT may lead to vascular damage that seems at least additive. PMID: 21097554 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4204642 Fri, 19 Nov 2010 00:00:00 +0100 4204642 http://www.medworm.com/index.php?rid=4187762&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21084427%26dopt%3DAbstract CONCLUSION: Consultation at a Radiological Conference in a tertiary center led to major changes in the management of 37% of the cancer patients presented and provided important information regarding the patient's disease in up to 50% of patients. PMID: 21084427 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4187762 Wed, 17 Nov 2010 00:00:00 +0100 4187762 http://www.medworm.com/index.php?rid=4187761&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21084428%26dopt%3DAbstract CONCLUSIONS: BRCA mutation status predicted OS independent of primary platinum sensitivity, suggesting that underlying tumor biology contributes to disease outcome and may be worthy of consideration in future clinical trial design. PMID: 21084428 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4187761 Wed, 17 Nov 2010 00:00:00 +0100 4187761 http://www.medworm.com/index.php?rid=4187760&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21084429%26dopt%3DAbstract CONCLUSIONS: GD and CD produced similar efficacy and toxicity profiles consistent with prior clinical experience. PMID: 21084429 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4187760 Wed, 17 Nov 2010 00:00:00 +0100 4187760 http://www.medworm.com/index.php?rid=4187763&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21078826%26dopt%3DAbstract CONCLUSION: Reducing the charge of therapy in this population did not diminish the efficacy of treatment. Further studies with this strategy, including biologicals, are warranted. PMID: 21078826 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4187763 Mon, 15 Nov 2010 00:00:00 +0100 4187763 http://www.medworm.com/index.php?rid=4172300&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21062969%26dopt%3DAbstract CONCLUSION: Using strict diagnostic criteria, there appears to be no difference in outcome between patients with FL3A and FL3B and no evidence of curability with anthracycline-based therapy. PMID: 21062969 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4172300 Tue, 09 Nov 2010 00:00:00 +0100 4172300 http://www.medworm.com/index.php?rid=4172306&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21059637%26dopt%3DAbstract CONCLUSION: This study could not demonstrate that high-dose chemotherapy given as part of first-line therapy improves outcome in patients with poor-prognosis GCC. PMID: 21059637 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4172306 Mon, 08 Nov 2010 00:00:00 +0100 4172306 http://www.medworm.com/index.php?rid=4172305&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21059638%26dopt%3DAbstract Authors: Sessa C, D'Incalci M PMID: 21059638 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4172305 Mon, 08 Nov 2010 00:00:00 +0100 4172305 http://www.medworm.com/index.php?rid=4172303&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21059639%26dopt%3DAbstract CONCLUSIONS: High-dose therapy added to the VACA-IE regimen in PR patients is feasible and effective. Selected groups of patients with ES can benefit from HDT. PMID: 21059639 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4172303 Mon, 08 Nov 2010 00:00:00 +0100 4172303 http://www.medworm.com/index.php?rid=4172301&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21059640%26dopt%3DAbstract CONCLUSION: Young patients, primary with non-metastatic disease and HER2+ tumors, have a high risk to develop CM in MBC. Survival of patients developing CM in the course of MBC is impaired compared with patients without CM. PMID: 21059640 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4172301 Mon, 08 Nov 2010 00:00:00 +0100 4172301 http://www.medworm.com/index.php?rid=4140465&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21048038%26dopt%3DAbstract CONCLUSION: No negative effect of systemic chemotherapy on neuropsychological test performance in TCPs at 1-year follow-up was found in this study. PMID: 21048038 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4140465 Wed, 03 Nov 2010 00:00:00 +0100 4140465 http://www.medworm.com/index.php?rid=4140464&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21048039%26dopt%3DAbstract CONCLUSION: Tumor EGFR copy number is not a predictive biomarker for the efficacy of cetuximab plus platinum/5-FU as first-line therapy for patients with R/M SCCHN. PMID: 21048039 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4140464 Wed, 03 Nov 2010 00:00:00 +0100 4140464 http://www.medworm.com/index.php?rid=4140463&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21048040%26dopt%3DAbstract CONCLUSIONS: Overall relapse rates were low in these patients and different mechanisms appeared to underlie local, nodal or distant relapse. PMID: 21048040 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4140463 Wed, 03 Nov 2010 00:00:00 +0100 4140463 http://www.medworm.com/index.php?rid=4140462&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21048041%26dopt%3DAbstract CONCLUSIONS: Our results support a genetic interaction between the TYMS enhancer region and VEGF +405G>C polymorphisms as a predictor of the efficacy of CAPOX-B in mCRC patients. PMID: 21048041 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4140462 Wed, 03 Nov 2010 00:00:00 +0100 4140462 http://www.medworm.com/index.php?rid=4140468&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21041375%26dopt%3DAbstract Authors: Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U PMID: 21041375 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4140468 Mon, 01 Nov 2010 00:00:00 +0100 4140468 http://www.medworm.com/index.php?rid=4140467&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21041376%26dopt%3DAbstract CONCLUSIONS: All types of cytopenia are common among patients with MDS and are risk factors for high rates of health care utilization and mortality. Management of the complications of MDS may improve patient outcomes. PMID: 21041376 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4140467 Mon, 01 Nov 2010 00:00:00 +0100 4140467 http://www.medworm.com/index.php?rid=4140466&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21041377%26dopt%3DAbstract Authors: Penack O, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Massenkeil G, Hentrich M, Salwender H, Wolf HH, Ostermann H Sepsis is a leading cause of mortality in neutropenic cancer patients. Early initiation of effective causative therapy as well as intensive adjunctive therapy is mandatory to improve outcome. We give recommendations for the management of adults with neutropenia and sepsis. The guidelines are written for clinicians involved in care of cancer patients and focus on pathophysiology, diagnosis and treatment of sepsis during neutropenia. PMID: 21041377 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4140466 Mon, 01 Nov 2010 00:00:00 +0100 4140466 http://www.medworm.com/index.php?rid=4125808&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21030381%26dopt%3DAbstract CONCLUSIONS: Patient enrollment in clinical trials and performing the biopsy at experienced institutions capable of undertaking the tumor resection without compromising the oncological and functional outcome should be pursued in the future. PMID: 21030381 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4125808 Thu, 28 Oct 2010 00:00:00 +0100 4125808 http://www.medworm.com/index.php?rid=4125807&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21030382%26dopt%3DAbstract Authors: Simkens LH, Tol J, Terstappen LW, Teerenstra S, Punt CJ, Nagtegaal ID PMID: 21030382 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4125807 Thu, 28 Oct 2010 00:00:00 +0100 4125807 http://www.medworm.com/index.php?rid=4125806&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21030383%26dopt%3DAbstract CONCLUSIONS: While GCT incidence was similar to neighboring Spain, the 5-year overall survival was lower than that of other European countries. This may result from delays in diagnosis, suggested by high proportion of high-stage and large-burden disease, and poor adherence to recommended treatment algorithms. PMID: 21030383 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4125806 Thu, 28 Oct 2010 00:00:00 +0100 4125806 http://www.medworm.com/index.php?rid=4125809&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21030380%26dopt%3DAbstract CONCLUSIONS: A robust care infrastructure supporting male fertility storage is needed urgently to include targeted information for cancer clinicians and patients, identified individuals responsible for coordination and documentation of discussions with patients. PMID: 21030380 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4125809 Wed, 27 Oct 2010 00:00:00 +0100 4125809 http://www.medworm.com/index.php?rid=4108761&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20974652%26dopt%3DAbstract CONCLUSION: Up to one-quarter of cancer cases and deaths would be preventable through appropriate control of infectious agents in Korea. PMID: 20974652 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4108761 Sun, 24 Oct 2010 23:00:00 +0100 4108761 http://www.medworm.com/index.php?rid=4108760&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20974653%26dopt%3DAbstract CONCLUSIONS: Training health professionals by CST is a promising approach to change communication behaviour and attitudes. Patients might also benefit from specifically trained health professionals but strong studies are lacking. However, feasibility and economic aspects have to be kept in mind when considering providing a training of optimal length. PMID: 20974653 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4108760 Sun, 24 Oct 2010 23:00:00 +0100 4108760 http://www.medworm.com/index.php?rid=4098576&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20966180%26dopt%3DAbstract Authors: Kassamali RH, Ganeshan A, Hoey ET, Crowe PM, Douis H, Henderson J Recent technological advances combined with innovative interventional radiology techniques can now offer an alternative less invasive treatment option for many patients with malignant vertebral body infiltration. Percutaneous vertebral augmentation procedures offer less invasive but effective pain relief to many patients with symptomatic spinal metastatic disease. The procedures are image guided and involve the injection of polymethylmethacrylate bone cement into the effected vertebral body. This technique can also be combined with radiofrequency ablation, which may accelerate vertebral stability. In this review, we examine the recent literature surrounding this topic and provide an overview of these emerging te... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4098576 Wed, 20 Oct 2010 23:00:00 +0100 4098576 http://www.medworm.com/index.php?rid=4098575&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20966181%26dopt%3DAbstract Authors: Roché H, Vahdat LT Increasing use of standard chemotherapy, especially anthracycline- and taxane-based therapies, in early-stage breast cancer has led to a corresponding increase in heavily pretreated and/or treatment-resistant cases of metastatic breast cancer (MBC). Thus, second and later lines of MBC therapy frequently involve the clinically challenging picture of progressive disease and limited treatment options. While several prognostic factors have been identified to aid treatment selection in MBC patients, treatment is palliative and aimed at prolonging survival, controlling symptoms, and maximizing patients' quality of life. No globally accepted standard exists for meeting these goals, and treatment patterns vary according to region. The list of available agents for t... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4098575 Wed, 20 Oct 2010 23:00:00 +0100 4098575 http://www.medworm.com/index.php?rid=4098574&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20966182%26dopt%3DAbstract Conclusion(s): The iPET interpretation assured low interobserver variability. High sensitivity for identification of pHL patients suffering relapse is achieved if [18F]-fluorodeoxyglucose uptake above the MBPS value is rated as a PET-positive finding. PMID: 20966182 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4098574 Wed, 20 Oct 2010 23:00:00 +0100 4098574 http://www.medworm.com/index.php?rid=4098573&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20966183%26dopt%3DAbstract CONCLUSION: The results from this first prospective study on rare gynecological cancers suggest that the MetS and its individual components may play a role in the development of these tumors. PMID: 20966183 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4098573 Wed, 20 Oct 2010 23:00:00 +0100 4098573 http://www.medworm.com/index.php?rid=4082379&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%26debug%3Dpubmeddembup%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F10%252F15%252001.40%2522%255BMHDA%255D%253A%25222010%252F10%252F19%252019.05%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F10%252F15%252001.40%2522%255BEDAT%255D%29%29 57 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/10/19PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4082379 Tue, 19 Oct 2010 23:05:03 +0100 4082379 http://www.medworm.com/index.php?rid=4066536&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%26debug%3Dpubmeddembup%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F10%252F09%252020.05%2522%255BMHDA%255D%253A%25222010%252F10%252F15%252001.40%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F10%252F09%252020.05%2522%255BEDAT%255D%29%29 17 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/10/15PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4066536 Fri, 15 Oct 2010 05:40:02 +0100 4066536 http://www.medworm.com/index.php?rid=4029706&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F09%252F30%252008.45%2522%255BMHDA%255D%253A%25222010%252F10%252F05%252003.10%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F09%252F30%252008.45%2522%255BEDAT%255D%29%29 32 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/10/05PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4029706 Tue, 05 Oct 2010 07:10:02 +0100 4029706 http://www.medworm.com/index.php?rid=4014416&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F09%252F20%252002.09%2522%255BMHDA%255D%253A%25222010%252F09%252F30%252008.45%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F09%252F20%252002.09%2522%255BEDAT%255D%29%29 53 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/09/30PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=4014416 Thu, 30 Sep 2010 12:45:02 +0100 4014416 http://www.medworm.com/index.php?rid=3982527&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20847032%26dopt%3DAbstract CONCLUSIONS: Dual-time FDG-PET/CT in patients with LARC treated with NCRT and radical surgery supplies limited predictive information. However, an optimal metabolic response appears associated with a favourable patient outcome. PMID: 20847032 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3982527 Wed, 15 Sep 2010 23:00:00 +0100 3982527 http://www.medworm.com/index.php?rid=3982528&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20843984%26dopt%3DAbstract CONCLUSIONS: From a health economic perspective, the addition of cetuximab to standard first-line chemotherapy in patients with epidermal growth factor receptor-expressing advanced NSCLC cannot be recommended to date, due to a high ICER compared with other health care interventions. Treatment schedules resulting in more favorable cost-utility ratios should be evaluated. PMID: 20843984 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3982528 Sun, 12 Sep 2010 23:00:00 +0100 3982528 http://www.medworm.com/index.php?rid=3976392&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20841323%26dopt%3DAbstract Authors: Peugniez C, Fantoni S, Leroyer A, Skrzypczak J, Duprey M, Bonneterre J PMID: 20841323 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3976392 Sun, 12 Sep 2010 23:00:00 +0100 3976392 http://www.medworm.com/index.php?rid=3958452&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20826716%26dopt%3DAbstract CONCLUSION: Among TKI-treated patients, increased EGFR gene copy number appears to be associated with improved survival outcomes. The effect on OS appears to be limited to patients of non-Asian descent. PMID: 20826716 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3958452 Tue, 07 Sep 2010 23:00:00 +0100 3958452 http://www.medworm.com/index.php?rid=3943568&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20819780%26dopt%3DAbstract CONCLUSIONS: The study population in ATHENA was more representative of general oncology practice than populations enrolled into randomised trials, although there may have been some bias towards younger, fitter patients. The safety and efficacy of bevacizumab-taxane therapy in this large study were consistent with results from randomised first-line trials. PMID: 20819780 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3943568 Sat, 04 Sep 2010 23:00:00 +0100 3943568 http://www.medworm.com/index.php?rid=3943569&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20813876%26dopt%3DAbstract CONCLUSIONS: The CTN has enabled consistent quality assured PET results to be obtained from multiple centres in time for clinical decision making. The results of trials will be significantly strengthened by this system. PMID: 20813876 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3943569 Wed, 01 Sep 2010 23:00:00 +0100 3943569 http://www.medworm.com/index.php?rid=3943575&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20810546%26dopt%3DAbstract CONCLUSION: Bortezomib is active in relapsed MALT lymphomas. Further investigations to identify optimal bortezomib dose, schedule, and combination regimens are needed since the frequent detection of dose-limiting peripheral neuropathy. PMID: 20810546 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3943575 Tue, 31 Aug 2010 23:00:00 +0100 3943575 http://www.medworm.com/index.php?rid=3943573&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20810547%26dopt%3DAbstract CONCLUSIONS: The combination of cetuximab, cisplatin, fluorouracil and radiotherapy leads to a very high proportion of CR and it is feasible with toxic effects similar to those expected by radiochemotherapy. The only unexpected toxicity was skin toxicity: grade 3 radiodermatitis occurred in 73% of the patients. PMID: 20810547 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3943573 Tue, 31 Aug 2010 23:00:00 +0100 3943573 http://www.medworm.com/index.php?rid=3903598&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20729535%26dopt%3DAbstract Authors: Ruggeri EM, Cecere FL, Moscetti L, Doni L, Padalino D, Di Costanzo F PMID: 20729535 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3903598 Thu, 26 Aug 2010 16:06:06 +0100 3903598 http://www.medworm.com/index.php?rid=3892156&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F08%252F17%252023.51%2522%255BMHDA%255D%253A%25222010%252F08%252F23%252015.30%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F08%252F17%252023.51%2522%255BEDAT%255D%29%29 55 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/08/23PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3892156 Mon, 23 Aug 2010 19:30:02 +0100 3892156 http://www.medworm.com/index.php?rid=3866305&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20705910%26dopt%3DAbstract CONCLUSION: Specialization and involvement in clinical research seem to be key elements for enhancing the quality of early breast cancer management at population level. PMID: 20705910 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3866305 Wed, 11 Aug 2010 23:00:00 +0100 3866305 http://www.medworm.com/index.php?rid=3866304&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20705911%26dopt%3DAbstract CONCLUSIONS: Single-agent sunitinib has modest activity in recurrent platinum-sensitive ovarian cancer, but only at the 50 mg intermittent dose schedule, suggesting that dose and schedule may be vital considerations in further evaluation of sunitinib in this cancer setting. PMID: 20705911 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3866304 Wed, 11 Aug 2010 23:00:00 +0100 3866304 http://www.medworm.com/index.php?rid=3866302&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20705912%26dopt%3DAbstract CONCLUSION: Diabetes is associated with increased mortality from selected cancers in Asian and non-Asian populations. PMID: 20705912 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3866302 Wed, 11 Aug 2010 23:00:00 +0100 3866302 http://www.medworm.com/index.php?rid=3866306&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20702788%26dopt%3DAbstract CONCLUSIONS: First-line treatment with bevacizumab and erlotinib in stage IIIb/IV NSCLC resulted in an NPR of 75%. OS was however disappointing. Early response evaluation with FDG-PET is the best predictive test for PFS. PMID: 20702788 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3866306 Tue, 10 Aug 2010 23:00:00 +0100 3866306 http://www.medworm.com/index.php?rid=3866308&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20699277%26dopt%3DAbstract Conclusion. Although PRES has predominantly been described in leukemia patients, it occurs in children with solid tumors as well. Hypertension seems to be the most important trigger for the occurrence of PRES during childhood cancer treatment. Seizures are the most common accompanying sign. Symptoms and radiological findings normalize in approximately 90% of the cases, but in 10% neurological symptoms remain. PMID: 20699277 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3866308 Mon, 09 Aug 2010 23:00:00 +0100 3866308